Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies
November 19, 2014 06:00 ET
|
Melinta Therapeutics, Inc.
$16.0 Million Will be Provided to Cover the Cost of the Study and Other Activities Specified in the Contract
Phase 1b and Phase 2/3 Studies Will Test Intravenous, Oral Capsule and Oral Suspension...